[ad_1]
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
Genome Insight, a global leader in Whole Genome Sequence analysis and interpretation, announced $23 million in Series B funding.
Dunamu & Partners led the financing with participation from InterVest, Signite Partners, KC, and VNTG Corporation, as well as existing investors DSC Investment, Paratus Investment, and Schmidt. The funding will be allocated towards advancing Genome Insight’s data production and curation pipelines that enable scalable investigation of whole-genome sequences (WGS), the most comprehensive technique for understanding the molecular origin of human diseases. These efforts will bring WGS in real-world clinics for clinicians and patients for next-generation medical practice, in particular, for cancer and rare diseases.
Genome Insight is a start-up company with expertise in the biomedical curation of WGS data. WGS examines the entire genomic sequence of diseased tissues, providing the most comprehensive characterization of tens of thousands …
Full story available on Benzinga.com
[ad_2]
Source link
